Artificial Intelligence-Driven Design and Optimization of Aerosolized Lorlatinib Nanocarriers for Precision Lung Cancer Therapy: Current Advances, Challenges, and Future Perspectives

Lung cancer continues to represent one of the most significant public health challenges worldwide, accounting for millions of new diagnoses and deaths annually. NSCLC constitutes approximately 85% of all lung cancer cases and remains a major contributor to cancer-associated mortality. Advances in molecular oncology have enabled the identification of specific genetic alterations responsible for tumor progression, leading to the development of targeted therapeutic approaches. Among these molecular targets, ALK rearrangements have emerged as critical oncogenic drivers. The development of ALK inhibitors has significantly improved clinical outcomes in affected patients. Lorlatinib represents a third-generation ALK inhibitor specifically designed to overcome resistance mutations that frequently develop during treatment with earlier-generation agents. Despite impressive therapeutic efficacy, conventional oral administration of Lorlatinib presents several limitations. Systemic exposure contributes to adverse effects including hyperlipidemia, neurocognitive disturbances, peripheral edema, and cardiovascular complications. Furthermore, oral administration cannot selectively concentrate drug molecules within lung tumors.

Pulmonary drug delivery offers a compelling alternative approach. Direct administration of aerosolized drug formulations into the respiratory tract enables enhanced local drug concentrations while potentially reducing systemic toxicity.

Recent developments in nanotechnology have further expanded the potential of pulmonary drug delivery systems. Nanoparticles provide controlled drug release, enhanced stability, improved cellular uptake, and tumor-targeting capabilities.

Concurrently, AI technologies are revolutionizing pharmaceutical research and development. Machine learning, deep learning, computational modeling, and digital twin technologies are increasingly utilized to optimize drug formulations, predict therapeutic outcomes, and personalize treatment strategies. The convergence of these three rapidly evolving fields—targeted oncology, pulmonary nanomedicine, and artificial intelligence—creates possible opportunities for improving lung cancer treatment.

Figure 1. Artificial Intelligence Integration Across the Development Pipeline of Aerosolized Lorlatinib Nanomedicine.

Figure 2. Proposed Mechanism of Improved Lung Tumor Targeting by Aerosolized Lorlatinib Nanoparticles Compared with Oral Administration.

Figure 3. AI-Assisted Computational Workflow for Predicting Pulmonary Deposition of Lorlatinib Nanoaerosols.

Figure 4. Translational Roadmap for AI-Driven Aerosolized Lorlatinib Development.

Figure 7. AI-Driven Optimization Loop for Aerosolized Lorlatinib Formulation Development.

Figure 8

Proposed Translational Development Pathway from Formulation Design to Clinical Application of Aerosolized Lorlatinib Nanoparticles.

CONCLUSION

The treatment landscape of ALK-positive non-small cell lung cancer has undergone a remarkable transformation with the introduction of targeted tyrosine kinase inhibitors, among which Lorlatinib represents one of the most advanced therapeutic options currently available. Its ability to overcome multiple resistance mutations and effectively penetrate the central nervous system has established Lorlatinib as a valuable treatment for patients with advanced and treatment-resistant disease. Nevertheless, conventional oral administration remains associated with several challenges, including systemic toxicity, off-target exposure, pharmacokinetic variability, and limited control over drug accumulation at the primary tumor site. These limitations continue to motivate the search for innovative drug delivery strategies capable of improving therapeutic precision while minimizing adverse effects. Pulmonary delivery of Lorlatinib-loaded nanoparticles offers a promising alternative approach by enabling direct drug administration to the lungs, the primary site of disease in most NSCLC patients. The unique physiological characteristics of the pulmonary system, including its large surface area, extensive vascular network, and thin epithelial barriers, provide an attractive platform for localized drug delivery. Through inhalation, aerosolized nanocarriers can potentially achieve higher drug concentrations within lung tumors while reducing systemic exposure and improving the overall therapeutic index. Such an approach may contribute not only to enhanced treatment efficacy but also to improved patient compliance and quality of life. Advances in nanotechnology have significantly expanded the possibilities for pulmonary drug delivery. Nanocarriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, and hybrid nanosystems provide opportunities to improve drug solubility, control release kinetics, enhance cellular uptake, and promote selective tumor targeting. Furthermore, the ability to engineer nanoparticle surface characteristics offers additional potential for active targeting and prolonged retention within the tumor microenvironment. Collectively, these advantages position nanotechnology as a critical component in the future development of inhalable anticancer therapies. A particularly exciting aspect of this emerging field is the integration of artificial intelligence into the design, optimization, and clinical translation of aerosolized nanomedicines. AI-driven methodologies, including machine learning, deep learning, computational fluid dynamics, digital twins, and predictive analytics, have the capacity to transform traditional pharmaceutical development processes. By identifying complex relationships among formulation variables, predicting aerosol performance, modeling pulmonary deposition patterns, and supporting patient-specific treatment planning, AI can substantially reduce development timelines while increasing formulation efficiency and precision. The convergence of AI with pulmonary nanomedicine represents a powerful multidisciplinary strategy that aligns closely with the goals of precision oncology. Despite these promising opportunities, several scientific, technological, and regulatory challenges remain unresolved. The successful development of aerosolized Lorlatinib nanoparticles will require careful optimization of particle size, aerodynamic behavior, formulation stability, drug loading capacity, and long-term storage characteristics. In addition, the biological complexity of the respiratory system, interpatient variability, and the potential for pulmonary toxicity necessitate rigorous preclinical and clinical evaluation. The implementation of AI-based systems also introduces concerns regarding model transparency, data quality, reproducibility, validation standards, and regulatory acceptance. Addressing these challenges will require close collaboration among pharmaceutical scientists, oncologists, engineers, computational researchers, regulatory authorities, and industry stakeholders. Future research should focus on the development of smart and adaptive nanocarrier systems capable of responding to tumor-specific microenvironmental cues, thereby enabling more precise drug release and improved therapeutic outcomes. The application of generative AI for novel carrier discovery, autonomous formulation platforms for rapid optimization, and digital twin technologies for individualized therapy design may further accelerate progress in this field. Additionally, combining aerosolized Lorlatinib nanocarriers with other therapeutic modalities, such as immunotherapy, gene therapy, or combination targeted therapies, may open new avenues for overcoming resistance mechanisms and improving long-term disease control. From a translational perspective, the integration of aerosol science, nanotechnology, and artificial intelligence has the potential to redefine how targeted therapies are developed and administered for lung cancer. Although aerosolized Lorlatinib nanomedicine remains largely at the conceptual and preclinical stage, the scientific rationale supporting its development is strong and supported by advances across multiple disciplines. Continued innovation and interdisciplinary research will be essential to bridge the gap between laboratory discoveries and clinical implementation. In conclusion, AI-assisted aerosolized Lorlatinib nanoparticles represent a highly promising next-generation strategy for precision lung cancer therapy. By combining the therapeutic power of targeted molecular inhibition with the advantages of localized pulmonary delivery and intelligent computational optimization, this approach has the potential to enhance treatment efficacy, reduce systemic toxicity, and contribute to the evolution of personalized oncology. While considerable work remains before clinical adoption can be achieved, the convergence of these technologies may ultimately establish a new paradigm for the management of ALK-positive NSCLC and serve as a model for future developments in cancer nanomedicine.

Ethical approval:  not applicable

Patient consent: not applicable

Funding:  no fund received.

REFERENCES

1. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–2029.
2. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1667.
3. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–1133.
4. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027–2039.
5. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al Alectinib versus crizotinib in untreated ALK-positive NSCLC. N Engl J Med. 2017;377(9):829–838.
6. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
7. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. J Aerosol Med Pulm Drug Deliv. 2007;20(3):241–260.
8. Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional lung deposition. J Control Release. 2011;150(1):1–14.
9. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009; 4:299–319.
10. Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery. Int J Mol Sci. 2014;15(4):5852–5873.
11. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, et al Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol. 2007;2(8):495–499.
12. Ehrhardt C. From nano to smart nanocarriers: pulmonary drug delivery. Expert Opin Drug Deliv. 2011;8(6):747–762.
13. Mehta P, Bothiraja C. Recent advances in inhalable nanocarrier-based systems. Drug Discov Today. 2020;25(11):1988–2001.
14. Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC. Design of inhalable nanoparticle systems for lung cancer therapy. Pharm Res. 2013;30(2):631–648.
15. Tzeng SY, Green JJ. Therapeutic nanomedicine for brain and lung cancers. Ther Deliv. 2013;4(6):687–704.
16. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012; 63:185–198.
17. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.
18. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR, et al Nanoparticle-based medicines: a review of FDA-approved materials. Pharm Res. 2016;33(10):2373–2387.
19. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles. Nat Rev Drug Discov. 2021;20(2):101–124.
20. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine. ACS Nano. 2013;7(6):552–556.
21. Topol EJ. High-performance medicine: the convergence of AI and human intelligence. Nat Med. 2019;25(1):44–56.
22. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477.
23. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80–93.
24. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, et al Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18(5):435–441.
25. Chan HP, Samala RK, Hadjiiski LM. Deep learning in medical image analysis. Med Phys. 2020;47(5): e1–e36.
26. Lin W, Wang Y, Yang Y, Shen Y. AI-assisted nanomedicine design and optimization. Adv Drug Deliv Rev. 2023; 198:114891.
27. Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs incorporating AI. BMJ. 2021;372: n206.
28. Viceconti M, Henney A, Morley-Fletcher E. In silico clinical trials: concepts and early applications. J Transl Med. 2016; 14:328.
29. Corral-Acero J, Margara F, Marciniak M, Rodero C, Loncaric F, Feng Y, et al The digital twin to enable precision cardiology. Nat Rev Cardiol. 2020;17(9):571–589.
30. Bruinenberg M, van Baal P, Hoes A. Digital twins in healthcare. NPJ Digit Med. 2022; 5:77.
31. Kleinstreuer C, Zhang Z. Airflow and particle transport in the human respiratory system. Annu Rev Fluid Mech. 2010; 42:301–334.
32. Longest PW, Hindle M. Aerosol deposition in the respiratory tract. J Aerosol Med Pulm Drug Deliv. 2011;24(2):79–99.
33. Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv. 2012;25(3):140–147.
34. Islam N, Gladki E. Dry powder inhalers and pulmonary drug delivery. Int J Nanomedicine. 2008;3(2):201–207.
35. Labiris NR, Dolovich MB. Pulmonary drug delivery. Br J Clin Pharmacol. 2003;56(6):588–599.
36. He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines. J Control Release. 2019;311-312:288–300.
37. Agrawal U, Sharma R, Gupta M, Vyas SP. Is nanotechnology a boon for oral and pulmonary drug delivery? Drug Discov Today. 2014;19(10):1530–1536.
38. Ventola CL. Big data and artificial intelligence in healthcare. P T. 2014;39(7):512–515.